sbi-101
Cell therapyexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2017 (NCT03015623)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Stem CellSupplementation
Stem Cell supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- sbi-101
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04445220 | Phase 1/Phase 2 (Phase 2) | Nov 19, 2020 | Sentien Biotechnologies, Inc. |
| NCT03015623 | Phase 1/Phase 2 (Phase 2) | May 1, 2017 | Sentien Biotechnologies, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sentien Biotechnologies, Inc. | For profit | 2 | 2 | 1 | 2017 |
1 organizations
Page 1 / 1